Bayer is testing Darolutamide in Prostate Cancer


The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

It is planned to include 555 participants.

Actual study start date is February 23, 2021. The researchers expect to complete the study by September 26, 2025.

One primary outcome measure is Radiological progression-free survival (rPFS), Time from the date of randomization to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first.

The location of the study, inclusion and exclusion criteria may be found here:

Clinical Research News

Upcoming Clinical Trials